Perrigo Co plc reported second-quarter 2026 results confirming ongoing execution of its Supply Chain Reinvention Program and consumer-led innovation strategy, reinforcing its position in private label self-care products across North America and key branded OTC categories in Europe. The company faces typical industry risks including customer concentration, regulatory compliance complexity, and supply chain vulnerabilities due to reliance on third-party and single-source suppliers. Its business model balances private label scale with targeted branded product investments, leveraging operational initiatives for cost efficiency. Monitoring supply chain metrics, regulatory outcomes, and customer diversification will be critical to assessing durable growth prospects.